TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast ( (MESO) ) has issued an announcement.
On November 21, 2025, Mesoblast Limited announced a collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to initiate a pivotal trial of Ryoncil® for adults with severe acute graft versus host disease (aGvHD) who are refractory to corticosteroids. This trial aims to extend the use of Ryoncil®, already FDA-approved for children, to adults, addressing a significant unmet need due to high mortality rates in patients failing existing therapies. The trial, set to begin enrollment in early 2026, represents a substantial market opportunity, potentially 3-4 times larger than the pediatric market.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score is driven by financial challenges and bearish technical indicators. Despite strong revenue growth and positive earnings call highlights, the company’s profitability issues and negative valuation metrics weigh heavily on the score. The potential for future growth, as indicated in the earnings call, provides some optimism.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform addresses severe inflammation by releasing anti-inflammatory factors, significantly reducing damaging inflammatory processes. Mesoblast’s Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients. The company is also developing additional cell therapies for various indications and has established commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 237,920
Technical Sentiment Signal: Buy
Current Market Cap: $1.91B
For an in-depth examination of MESO stock, go to TipRanks’ Overview page.